T. Huzarski

发表

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

B. Karlan, P. Møller, J. Lubiński, 2014, Breast Cancer Research and Treatment.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

W. Foulkes, L. Salmena, J. Lubiński, 2012, Breast Cancer Research.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS genetics.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Lara E. Sucheston-Campbell, 2017, Nature Genetics.

Breast cancer predisposing alleles in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2005, Breast Cancer Research and Treatment.

The risk of breast cancer in women with a BRCA1 mutation from North America and Poland

Susan L Neuhausen, Jan Lubinski, Kevin Sweet, 2012, International journal of cancer.

CHEK2 is a multiorgan cancer susceptibility gene.

J. Lubiński, S. Narod, E. Grabowska, 2004, American journal of human genetics.

Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

B. Karlan, W. Foulkes, J. Lubiński, 2012, Cancer Epidemiology, Biomarkers & Prevention.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Christiana Kartsonaki, Mads Thomassen, Julian Peto, 2010, Nature Genetics.

BRCA1-positive breast cancers in young women from Poland

W. Kozlowski, J. Ryś, K. Lamperska, 2006, Breast Cancer Research and Treatment.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

Mads Thomassen, Etienne Rouleau, Dieter Niederacher, 2010, Cancer research.

Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland

J. Kładny, R. Scott, A. Jakubowska, 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers

B. Karlan, P. Møller, W. Foulkes, 2018, JAMA oncology.

The 3′ untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation

R. Scott, U. Hamann, A. Jakubowska, 2007, Breast Cancer Research and Treatment.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, T. Park-Simon, 2021, The Lancet. Oncology.

Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study

A. Jakubowska, J. Lubiński, Katarzyna Jaworska, 2012, Cancer Causes and Control.

Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

A. Whittemore, M. Beckmann, P. Fasching, 2020, Cancer Epidemiology, Biomarkers & Prevention.

A common variant of CDKN2A (p16) predisposes to breast cancer

S. Narod, C. Szczylik, A. Mackiewicz, 2005, Journal of Medical Genetics.

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families

R. Scott, J. Lubiński, C. Cybulski, 2015, Hereditary cancer in clinical practice.

The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland

P. Jarzemski, A. Jakubowska, J. Lubiński, 2013, The Prostate.

Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer

R. Scott, J. Lubiński, T. Grodzki, 2005, Breast Cancer Research and Treatment.

Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers

J. Lubiński, W. Wąsowicz, T. Huzarski, 2009, Cancer Epidemiology, Biomarkers & Prevention.

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

J. Kładny, J. Lubiński, S. Narod, 2009, Breast Cancer Research and Treatment.

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

J. Lubiński, S. Narod, C. Cybulski, 2014, Breast Cancer Research and Treatment.

Early radiation exposures and BRCA1-associated breast cancer in young women from Poland

J. Lubiński, S. Narod, F. Leeuwen, 2008, Breast Cancer Research and Treatment.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

B. Karlan, P. Møller, W. Foulkes, 2017, Journal of the National Cancer Institute.

Serum Selenium Level and 10-Year Survival after Melanoma

A. Jakubowska, J. Lubiński, C. Cybulski, 2021, Biomedicines.

Serum selenium level and cancer risk: a nested case-control study

A. Jakubowska, J. Lubiński, Katarzyna Jaworska-Bieniek, 2019, Hereditary Cancer in Clinical Practice.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2018, Gynecologic oncology.

Distal intramural spread of rectal cancer after preoperative radiotherapy: the results of a multicenter randomized clinical study.

E. Chmielik, K. Bujko, A. Karmoliński, 2006, International journal of radiation oncology, biology, physics.

SHORT REPORT Elevated level of 8-oxo-7,8-dihydro-2 0 -deoxyguanosine in leukocytes of BRCA1

J. Lubiński, T. Huzarski, D. Gackowski, 2009 .

Elevated level of 8‐oxo‐7,8‐dihydro‐2′‐deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls

J. Lubiński, T. Huzarski, D. Gackowski, 2009, International journal of cancer.

Vitamin D receptor variants and the malignant melanoma risk: a population-based study.

C. Cybulski, T. Byrski, T. Huzarski, 2009, Cancer epidemiology.

Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility

J. Kładny, R. Scott, J. Lubiński, 2010, BMC Cancer.

Vitamin D receptor variants and breast cancer risk in the Polish population

J. Kładny, J. Lubiński, C. Cybulski, 2009, Breast Cancer Research and Treatment.

CYP1B1 and predisposition to breast cancer in Poland

R. Scott, A. Jakubowska, J. Lubiński, 2007, Breast Cancer Research and Treatment.

Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.

J. Lubiński, S. Narod, P. Sun, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland

J. Kładny, A. Jakubowska, S. Narod, 2021, Biomedicines.

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

J. Lubiński, A. Eisen, S. Narod, 2012, Breast Cancer Research.

Inherited variants in XRCC2 and the risk of breast cancer

A. Jakubowska, J. Lubiński, S. Narod, 2019, Breast Cancer Research and Treatment.

Recurrent mutations of BRCA1 and BRCA2 in Poland: an update

A. Jakubowska, J. Lubiński, S. Narod, 2015, Clinical genetics.

The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania

J. Lubiński, S. Narod, C. Cybulski, 2017, Clinical genetics.

Integrin b 3 Leu33Pro polymorphism increases BRCA1 associated ovarian cancer risk

U. Hamann, A. Jakubowska, J. Lubiński, 2007 .

Integrin β3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk

R. Scott, U. Hamann, A. Jakubowska, 2007, Journal of Medical Genetics.

Direct-to-patient BRCA1 testing: the Twoj Styl experience

J. Lubiński, S. Narod, K. Metcalfe, 2006, Breast Cancer Research and Treatment.

Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2

J. Lubiński, S. Narod, J. Masson, 2022, JCO precision oncology.

BRCA2 gene mutations in families with aggregations of breast and stomach cancers

R. Scott, A. Jakubowska, J. Lubiński, 2002, British Journal of Cancer.

DNA Variation in MSR1, RNASEL and E-Cadherin Genes and Prostate Cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2007, Urologia Internationalis.

Selenium as marker for cancer risk and prevention.

J. Kładny, S. Gupta, A. Jakubowska, 2012, Polski przeglad chirurgiczny.

Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

O. Olopade, B. Karlan, P. Møller, 2018, International journal of epidemiology.

The 3020insC allele of NOD2 predisposes to early-onset breast cancer

J. Lubiński, S. Narod, T. Byrski, 2004, Breast Cancer Research and Treatment.

Serum selenium levels predict survival after breast cancer

J. Kładny, A. Jakubowska, J. Lubiński, 2017, Breast Cancer Research and Treatment.

Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population

R. Scott, A. Jakubowska, J. Lubiński, 2018, PLoS ONE.

The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers

B. Karlan, J. Lubiński, S. Neuhausen, 2018, International journal of cancer.

BARD1 and breast cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2007, Breast Cancer Research and Treatment.

Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers.

A. Jakubowska, J. Lubiński, C. Cybulski, 2003, Journal of Applied Genetics.

Synergistic interaction of variants in and on breast cancer risk

Bogdanova, T. Dörk, C. Cybulski, 2020 .

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

A. Oza, M. Friedlander, N. Colombo, 2022, Gynecologic oncology.

Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

Stephanie A Cohen, O. Olopade, B. Karlan, 2021, Breast Cancer Research and Treatment.

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers

J. Lubiński, S. Narod, J. Kotsopoulos, 2019, Breast Cancer Research and Treatment.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

NOD2 variants and the risk of malignant melanoma

C. Cybulski, T. Byrski, T. Huzarski, 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms

R. Eils, R. Scott, U. Hamann, 2009, Breast Cancer Research and Treatment.

Hereditary ovarian cancer in Poland.

A. Jakubowska, J. Lubiński, S. Narod, 2004, International journal of cancer.

Hereditary ovarian cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2003 .

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

W. Foulkes, S. Neuhausen, M. Robson, 2014, Current oncology.

Male to female ratio among offspring of BRCA1 mutation carriers

J. Lubiński, S. Narod, T. Byrski, 2006, Breast Cancer Research and Treatment.

Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2003, Journal of medical genetics.

Transmission of mutant alleles to female offspring of BRCA1 carriers in Poland.

A. Jakubowska, J. Lubiński, T. Byrski, 2005, Journal of Medical Genetics.

Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer

Nussbaum, S. Cross, P. Fasching, 2016 .

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer

J. Kładny, A. Jakubowska, J. Lubiński, 2021, Nutrients.

Weight Gain After Oophorectomy Among Women with a BRCA1 or BRCA2 Mutation

W. Foulkes, S. Friedman, J. Lubiński, 2015, Women's health.

A common nonsense mutation of the BLM gene and prostate cancer risk and survival.

P. Jarzemski, A. Jakubowska, J. Lubiński, 2013, Gene.

Detection of germline mutations in the BRCA1 gene by RNA‐based sequencing

A. Jakubowska, J. Lubiński, C. Cybulski, 2001, Human mutation.

The 3020insC allele of NOD2 predisposes to early-onset breast cancer

J. Lubiński, Micha, S. Narod, 2004, Breast Cancer Research and Treatment.

Common variants of DNA repair genes and malignant melanoma.

J. Kładny, A. Jakubowska, C. Cybulski, 2008, European journal of cancer.

CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland

A. Jakubowska, J. Lubiński, Katarzyna Jaworska, 2010, Familial Cancer.

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism

R. Scott, U. Hamann, A. Jakubowska, 2008, BMC Cancer.

Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

O. Olopade, W. Foulkes, K. Offit, 2013, Breast Cancer Research and Treatment.

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor

A. Jakubowska, J. Lubiński, C. Cybulski, 2022, Hereditary Cancer in Clinical Practice.

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer

A. Jakubowska, J. Lubiński, S. Narod, 2021, Cancers.

CDKN2A common variants and their association with melanoma risk: a population-based study.

J. Kładny, R. Scott, J. Lubiński, 2005, Cancer research.

breast cancer A common variant of CDKN2A (p16) predisposes to

S. Narod, C. Szczylik, A. Mackiewicz, 2005 .

The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.

R. Scott, U. Hamann, A. Jakubowska, 2008, Cancer letters.

Germline RECQL mutations are associated with breast cancer susceptibility

Aniruddh Kashyap, Jacek Majewski, Javad Nadaf, 2015, Nature Genetics.

Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility

W. Foulkes, A. Jakubowska, J. Lubiński, 2016, Nature Genetics.

Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?

J. Kładny, J. Lubiński, S. Narod, 2007, European Journal of Human Genetics.

A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.

J. Lubiński, S. Narod, J. Kotsopoulos, 2019, Gynecologic oncology.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States

J. Kładny, A. Jakubowska, K. Safranow, 2002, Journal of medical genetics.

The CYP17A1 −34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers

E. Ziv, D. Easton, G. Chenevix-Trench, 2011, Breast Cancer Research and Treatment.

Predictors of survival for breast cancer patients with a BRCA1 mutation

J. Lubiński, S. Narod, P. Sun, 2018, Breast Cancer Research and Treatment.

A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population

A. Jakubowska, J. Lubiński, S. Narod, 2008, Breast Cancer Research and Treatment.

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer

A. Jakubowska, J. Lubiński, S. Narod, 2020, International journal of cancer.

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Nicholas A. Sinnott-Armstrong, Richard C. Sallari, S. Cross, 2016, Nature Genetics.

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

J. Lubiński, C. Cybulski, T. Byrski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E Sucheston-Campbell, A. Whittemore, M. Beckmann, 2016, Cancer Epidemiology, Biomarkers & Prevention.

CDKN2A-positive breast cancers in young women from Poland

A. Jakubowska, J. Lubiński, S. Narod, 2007, Breast Cancer Research and Treatment.

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Yurii B. Shvetsov, M. Beckmann, A. Talhouk, 2022, British Journal of Cancer.

XPD Common Variants and their Association with Melanoma and Breast Cancer Risk

J. Kładny, C. Cybulski, T. Byrski, 2006, Breast Cancer Research and Treatment.

CDKN 2 A Common Variants and Their Association with Melanoma Risk : A Population-Based Study

J. Kładny, R. Scott, J. Lubiński, 2005 .

CDKN2A common variant and multi‐organ cancer risk—a population‐based study

R. Scott, J. Lubiński, S. Narod, 2006, International journal of cancer.

CDKN 2 A common variant and multi-organ cancer risk — a population-based study

R. Scott, J. Lubiński, S. Narod, 2006 .

SHORT REPORT CDKN2A common variant and multi-organ cancer risk—a population-based study

R. Scott, J. Lubiński, S. Narod, 2006 .

Clinical characteristics of breast cancer in patients with an NBS1 mutation

A. Jakubowska, J. Lubiński, S. Narod, 2013, Breast Cancer Research and Treatment.

Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study

A. Jakubowska, J. Lubiński, Katarzyna Jaworska, 2012, Cancer Causes & Control.

Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

O. Olopade, B. Karlan, P. Møller, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

L. Kiemeney, R. Vierkant, Jingmei Li, 2020, bioRxiv.

Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers

A. Jakubowska, Tomáš Matoušek, S. Domchek, 2021, Cancers.

Blood arsenic levels and the risk of familial breast cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2019, International journal of cancer.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

W. Foulkes, L. Salmena, J. Lubiński, 2012, Breast Cancer Research.

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.

Victoria L. Cafourek, S. Cross, M. Beckmann, 2011, Journal of the National Cancer Institute.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

V. Pankratz, F. Couch, B. Bonanni, 2012, British Journal of Cancer.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

Patrick Neven, Päivi Heikkilä, Giu-Cheng Hsu, 2011, Human molecular genetics.

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

Patrick Neven, Peter Kraft, Nazneen Rahman, 2015 .

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, B. Fridley, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic predisposition to male breast cancer in Poland

J. Lubiński, S. Narod, C. Cybulski, 2021, BMC Cancer.

Hereditary breast and ovarian cancer

J. Lubiński, T. Byrski, T. Huzarski, 2008, Hereditary Cancer in Clinical Practice.

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.

A. Jakubowska, J. Lubiński, S. Narod, 2000, American journal of human genetics.

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland

A. Jakubowska, J. Lubiński, S. Narod, 2020, Cancers.

The spectrum of mutations predisposing to familial breast cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2019, International journal of cancer.

New EPCAM founder deletion in Polish population

A. Pławski, T. Byrski, T. Huzarski, 2017, Clinical genetics.

Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.

A. Jakubowska, J. Lubiński, S. Narod, 2015, The Lancet. Oncology.

Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families

J. Lubiński, C. Cybulski, T. Huzarski, 2013, Molecular Biology Reports.

J. Lubiński, E. Chmielik, B. Jarzab, 2011, Frontiers in bioscience.

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

J. Lubiński, S. Narod, T. Mierzwa, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.

T. Huzarski, P. Serrano-Fernández, B. Masojć, 2009, Anticancer research.

Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology

J. Kładny, R. Scott, A. Jakubowska, 2009, Breast Cancer Research and Treatment.

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

J. Lubiński, T. Mierzwa, T. Byrski, 2008, Breast Cancer Research and Treatment.

A survey of preventive measures among BRCA1 mutation carriers from Poland

J. Lubiński, S. Narod, P. Sun, 2007, Clinical genetics.

The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers

R. Scott, U. Hamann, A. Jakubowska, 2007, Cancer Epidemiology Biomarkers & Prevention.

The RAD 51 135 G > C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA 1 Mutation Carriers

R. Scott, U. Hamann, A. Jakubowska, 2007 .

Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks

R. Scott, U. Hamann, A. Jakubowska, 2007, Breast Cancer Research and Treatment.

Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status

J. Lubiński, A. Monteiro, S. Narod, 2005, Journal of Medical Genetics.

The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs

A. Jakubowska, J. Lubiński, S. Narod, 2005 .

A high proportion of founder BRCA1 mutations in Polish breast cancer families

A. Jakubowska, J. Lubiński, S. Narod, 2004, International journal of cancer.

Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.

A. Jakubowska, J. Lubiński, T. Byrski, 2004, Journal of applied genetics.

A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer

R. Scott, A. Jakubowska, J. Lubiński, 2003, European Journal of Human Genetics.

Molecular Analyses in Diagnosis of High Genetic Predispositions to Malignancies

J. Kładny, A. Jakubowska, J. Lubiński, 2000 .

BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation

T. Dörk, N. Bogdanova, A. Jakubowska, 2019, Cancers.

Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland

A. Jakubowska, J. Lubiński, S. Narod, 2015, Clinical genetics.

University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch,

F. Couch, B. Bonanni, O. Olopade, 2013 .

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Yurii B. Shvetsov, M. Pike, A. Talhouk, 2022, Cancer.

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

Sebastian M. Armasu, A. Whittemore, P. Fasching, 2018, The journal of pathology. Clinical research.

Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer

A. Jakubowska, J. Lubiński, S. Narod, 2019, Cancers.

Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer

J. Lubiński, C. Cybulski, D. Wokołorczyk, 2012, Breast Cancer Research and Treatment.

RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

F. Couch, O. Olopade, T. Rebbeck, 2007, American journal of human genetics.

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband

J. Lubiński, S. Narod, P. Sun, 2009, British Journal of Cancer.

Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?

A. Jakubowska, J. Lubiński, S. Narod, 2021, Cancers.

PALB2 mutations and prostate cancer risk and survival

P. Jarzemski, A. Jakubowska, S. Narod, 2021, British Journal of Cancer.

Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2020, International journal of cancer.

Inherited NBN Mutations and Prostate Cancer Risk and Survival

A. Jakubowska, J. Lubiński, C. Cybulski, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men

A. Jakubowska, J. Lubiński, S. Narod, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles

K. Muir, A. Lophatananon, A. Borkowski, 2013, British Journal of Cancer.

An inherited NBN mutation is associated with poor prognosis prostate cancer

A Jakubowska, A. Borkowski, P. Jarzemski, 2012, British Journal of Cancer.

CHEK2 mutations and HNPCC‐related colorectal cancer

J. Kładny, A. Jakubowska, J. Lubiński, 2010, International journal of cancer.

Estrogen receptor status in CHEK2‐positive breast cancers: implications for chemoprevention

A. Jakubowska, J. Lubiński, C. Cybulski, 2009, Clinical genetics.

Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers.

A. Jakubowska, J. Lubiński, S. Narod, 2008, Carcinogenesis.

BRCA1 mutations and prostate cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27

J. Kładny, A. Jakubowska, J. Lubiński, 2007, Cancer Epidemiology Biomarkers & Prevention.

Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?

J. Kładny, J. Lubiński, S. Narod, 2007, European Journal of Human Genetics.

A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer

A. Borkowski, A. Jakubowska, J. Lubiński, 2006, Journal of Medical Genetics.

cancerwith an increased risk of prostate A large germline deletion in the Chek2 kinase gene

A. Jakubowska, J. Lubiński, R. Zdrojowy, 2006 .

A novel founder CHEK2 mutation is associated with increased prostate cancer risk.

J. Lubiński, R. Czajka, S. Narod, 2004, Cancer research.

Advances in Brief A Novel Founder CHEK 2 Mutation is Associated with Increased Prostate Cancer Risk

J. Lubiński, R. Czajka, S. Narod, 2004 .

A Novel Founder CHEK 2 Mutation is Associated with Increased Prostate Cancer Risk

R. Czajka, S. Narod, C. Cybulski, 2004 .

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2018, British Journal of Cancer.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study

Charis Eng, Fergus Couch, Kevin Sweet, 2013, British Journal of Cancer.

Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers

Joshua M. Korn, M. Daly, D. Altshuler, 2011, Human Genetics.

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.

Jae-Weon Kim, V. Gebski, A. Oza, 2020, European journal of cancer.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Jane E. Carpenter, A. Whittemore, W. Chung, 2016, Nature Communications.

An Unusual Case of Vulvar Involvement in the Course of Granulomatosis with Polyangiitis

K. Nowak, T. Huzarski, E. Gołembiewska, 2022, International journal of environmental research and public health.

813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

The presence of prostate cancer at biopsy is predicted by a number of genetic variants

P. Jarzemski, A. Jakubowska, J. Lubiński, 2014, International journal of cancer.

V. Gebski, D. Provencher, D. Eek, 2018, The Lancet. Oncology.

Survival in patients with rare subtypes of renal cell carcinoma

T. Huzarski, M. Grabowski, J. Lubiński, 2002, BJU international.

The role of tamoxifen in chemoprevention of inherited breast cancer in BRCA1 mutation carriers

A. Jakubowska, J. Lubiński, T. Byrski, 2003 .

Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population

A. Jakubowska, J. Lubiński, K. Durda, 2020, Hereditary Cancer in Clinical Practice.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

J. Lubiński, P. Domagała, T. Huzarski, 2011, Breast Cancer Research and Treatment.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Survival from breast cancer in patients with CHEK2 mutations

R. Wiśniowski, A. Jakubowska, J. Lubiński, 2014, Breast Cancer Research and Treatment.

Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.

A. Jakubowska, J. Lubiński, S. Narod, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations

A. Jakubowska, J. Lubiński, M. Błasińska-Morawiec, 2022, British Journal of Cancer.

Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

W. Foulkes, S. Friedman, J. Lubiński, 2015, Breast Cancer Research and Treatment.

Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland

J. Lubiński, S. Narod, P. Sun, 2005, Breast Cancer Research and Treatment.

Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study)

J. Kładny, A. Jakubowska, K. Safranow, 2005, Clinical genetics.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

David G. Morris, Kylie L. Gorringe, M. Pike, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk

Thilo Dörk, Natalia Bogdanova, Tadeusz Dębniak, 2009, Breast Cancer Research and Treatment.

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland

A. Jakubowska, J. Lubiński, S. Narod, 2007, Breast Cancer Research and Treatment.

CHEK2-Positive Breast Cancers in Young Polish Women

A. Jakubowska, J. Lubiński, S. Narod, 2006, Clinical Cancer Research.

Immunophenotypic predictive profiling of BRCA1-associated breast cancer

Pawel Domagala, Jan Lubinski, Tomasz Huzarski, 2010, Virchows Archiv.

Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population

R. Scott, A. Jakubowska, J. Lubiński, 2020, Breast Cancer.

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, W. Foulkes, W. Meschino, 2018, Breast Cancer Research and Treatment.

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study

B. Karlan, P. Møller, W. Foulkes, 2016, Breast Cancer Research and Treatment.

Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?

B. Karlan, W. Foulkes, J. Iqbal, 2015, Breast Cancer Research and Treatment.

Allelic modification of breast cancer risk in women with an NBN mutation

A. Jakubowska, J. Lubiński, S. Narod, 2019, Breast Cancer Research and Treatment.

Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170

Wei Zheng, Mads Thomassen, Nicholas A. Sinnott-Armstrong, 2016 .

Gene Expression Profiling in Hereditary , BRCA 1-linked Breast Cancer : Preliminary Report

J. Lubiński, E. Chmielik, K. Lisowska, 2015 .

Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report

J. Lubiński, E. Chmielik, K. Lisowska, 2006, Hereditary cancer in clinical practice.

Increased Rates of Chromosome Breakage in BRCA1 Carriers Are Normalized by Oral Selenium Supplementation

J. Lubiński, S. Narod, T. Huzarski, 2005, Cancer Epidemiology Biomarkers & Prevention.

Low Blood-As Levels and Selected Genotypes Appears to Be Promising Biomarkers for Occurrence of Colorectal Cancer in Women

J. Kładny, R. Scott, A. Jakubowska, 2021, Biomedicines.

Pathology of breast cancer in women with constitutional CHEK2 mutations

J. Lubiński, S. Narod, C. Cybulski, 2005, Breast Cancer Research and Treatment.

Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations

A Jakubowska, T. Dörk, A. Jakubowska, 2008, Journal of Medical Genetics.

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

A. Oza, D. Berton, J. Ledermann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2016, International journal of epidemiology.

The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients

J. Lubiński, S. Narod, P. Sun, 2016, Breast Cancer Research and Treatment.

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

A range of cancers is associated with the rs6983267 marker on chromosome 8.

A. Jakubowska, J. Lubiński, S. Narod, 2008, Cancer research.

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome

J. Lubiński, C. Cybulski, W. Kluźniak, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?

J. Kładny, A. Jakubowska, J. Lubiński, 2016, International journal of cancer.

DNA testing for variants conferring low or moderate increase in the risk of cancer

J. Lubiński, C. Cybulski, T. Huzarski, 2008, Hereditary cancer in clinical practice.

MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk

J. Kładny, R. Scott, J. Lubiński, 2006, International journal of cancer.

Coverage of the Genetic Background of Breast Cancer in the Polish Population

A. Jakubowska, J. Lubiński, C. Cybulski, 2006, Hereditary cancer in clinical practice.

Low-risk Genes and Multi-organ Cancer Risk in the Polish Population

R. Scott, A. Jakubowska, J. Lubiński, 2006, Hereditary cancer in clinical practice.

Serum selenium level and cancer risk: a nested case-control study

A. Jakubowska, J. Lubiński, S. Narod, 2019, Hereditary cancer in clinical practice.

Selenium as a marker of cancer risk and of selection for control examinations in surveillance

J. Kładny, R. Scott, A. Jakubowska, 2015, Contemporary oncology.

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet

J. Lubiński, S. Narod, C. Cybulski, 2006, Hereditary cancer in clinical practice.

Selenium and the risk of cancer in BRCA1 carriers

A. Jakubowska, J. Lubiński, K. Durda, 2011, Hereditary Cancer in Clinical Practice.

Are two-centimeter breast cancers large or small?

J. Iqbal, A. Jakubowska, J. Lubiński, 2013, Current oncology.

Impact of Inertial Training on Muscle Strength and Quality of Life in Breast Cancer Survivors

T. Huzarski, M. Naczk, J. Doś, 2022, International journal of environmental research and public health.

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

A. Oza, J. Ledermann, M. Friedlander, 2017 .

V. Gebski, D. Provencher, D. Eek, 2017 .

Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.

D. Provencher, J. Ledermann, T. Park-Simon, 2017 .

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families

R. Scott, J. Lubiński, C. Cybulski, 2015, Hereditary cancer in clinical practice.

Lynch syndrome mutations shared by the Baltic States and Poland

J. Kładny, A. Metspalu, T. Byrski, 2014, Clinical genetics.

Variants in ATRIP are associated with breast cancer susceptibility in the Polish population and UK Biobank.

A. Jakubowska, S. Narod, J. Masson, 2023, American journal of human genetics.

BRCA1 mutations and colorectal cancer in Poland

Anna Jakubowska, Rafał Wiśniowski, Tadeusz Dębniak, 2010, Familial Cancer.

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, P. Møller, W. Foulkes, 2014, Breast Cancer Research and Treatment.

Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation.

J. Lubiński, S. Narod, T. Huzarski, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC).

J. Lubiński, S. Narod, C. Cybulski, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

V. Gebski, M. Friedlander, B. Ataseven, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer susceptibility genes.

J. Kładny, R. Scott, A. Jakubowska, 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

965PEvaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)

A. Oza, C. Scott, I. Vergote, 2017 .

Survival from breast cancer in women with a BRCA2 mutation by treatment

F. Couch, P. Møller, W. Foulkes, 2021, British Journal of Cancer.

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

F. Couch, O. Olopade, P. Møller, 2023, Breast Cancer Research and Treatment.

Population screening for cancer family syndromes in West-Pomeranian Region of Poland with 1.7 min inhabitants

C. Cybulski, T. Byrski, T. Huzarski, 2004 .

Serum Essential Elements and Survival after Cancer Diagnosis

A. Jakubowska, S. Narod, P. Sun, 2023, Nutrients.

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population

A. Jakubowska, S. Narod, C. Cybulski, 2023, Genes.

The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first‐degree relative with breast cancer

H T Lynch, B. Karlan, W. Foulkes, 2018, Clinical genetics.

ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.

A. Oza, E. Swisher, I. Bondarenko, 2017 .

Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families

J. Lubiński, C. Cybulski, T. Huzarski, 2013, Molecular Biology Reports.

Risk of Second Primary Thyroid Cancer in Women with Breast Cancer

A. Jakubowska, J. Lubiński, S. Narod, 2022, Cancers.

987TiPOReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer

R. Glasspool, F. Marmé, B. Asselain, 2017 .

Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients

J. Kładny, J. Lubiński, R. Słomski, 2011, The Journal of molecular diagnostics : JMD.

Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.

U. Hamann, A. Jakubowska, J. Lubiński, 2007, Journal of Medical Genetics.

Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland

J. Lubiński, C. Cybulski, T. Byrski, 2006, Hereditary Cancer in Clinical Practice.

Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer

J. Lubiński, S. Narod, A. Mackiewicz, 2017, Hereditary Cancer in Clinical Practice.

Genetic testing for hereditary breast cancer in Poland: 1998–2022

A. Jakubowska, S. Narod, C. Cybulski, 2023, Hereditary Cancer in Clinical Practice.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

V. Pankratz, F. Couch, O. Olopade, 2010, Cancer research.

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers

O. Olopade, T. Rebbeck, R. Eeles, 2011 .

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum selenium levels predict survival after breast cancer

J. Kładny, A. Jakubowska, S. Narod, 2017, Breast Cancer Research and Treatment.

V. Gebski, A. Oza, J. Ledermann, 2017, The Lancet. Oncology.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.

B. Fridley, E. Goode, D. Bowtell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

S. Narod, C. Cybulski, T. Byrski, 2011, Hereditary Cancer in Clinical Practice.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

V. Pankratz, F. Couch, T. Rebbeck, 2011, Human molecular genetics.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

A. Whittemore, F. Couch, B. Bonanni, 2015 .

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

Jaana M. Hartikainen, Sandra L. Halverson, A. Whittemore, 2015, Nature Genetics.

Blood Cadmium Level Is a Marker of Cancer Risk in Men

A. Jakubowska, C. Cybulski, T. Huzarski, 2024, Nutrients.

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.

V. Gebski, A. Oza, J. Ledermann, 2021, European journal of cancer.

Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers

A. Jakubowska, C. Cybulski, T. Huzarski, 2024, Antioxidants.

Correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients

A. Jakubowska, M. Słojewski, C. Cybulski, 2024, Nutrients.

Analytical sensitivity of a method is critical in detection of low-level BRCA1 constitutional epimutation

J. Lubiński, T. Huzarski, Dominik Strapagiel, 2023, Scientific reports.